MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients

Cytarabine is the primary chemotherapeutic agent used for treatment of acute myeloid leukemia (AML). Disease relapse after initial remission remains one of the most pressing therapeutic challenges in the treatment of AML. Relapsed disease is often resistant to cytarabine and subsequent salvage thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhise, Neha S., Chauhan, Lata, Shin, Miyoung, Cao, Xueyuan, Pounds, Stanley, Lamba, Vishal, Lamba, Jatinder K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729948/
https://www.ncbi.nlm.nih.gov/pubmed/26858643
http://dx.doi.org/10.3389/fphar.2015.00324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729948/
https://www.ncbi.nlm.nih.gov/pubmed/26858643
http://dx.doi.org/10.3389/fphar.2015.00324

Ejemplares similares